Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study - Report - MDSpire
Advertisement
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
Phase 3 Trial: Gecacitinib vs Hydroxyurea in Intermediate-2/High-Risk Myelofibrosis
Overview
This phase 3 randomized trial compared the efficacy and safety of gecacitinib, a novel JAK and ACVR1 inhibitor, against hydroxyurea (HU) in JAK inhibitor-naïve intermediate-2 or high-risk myelofibrosis patients. Final results demonstrated that gecacitinib showed superior spleen volume reduction and a favorable safety profile compared to HU.
Background
Myelofibrosis (MF) is a BCR::ABL1-negative myeloproliferative neoplasm characterized by splenomegaly, systemic symptoms, and cytopenias, with a high incidence of anemia especially in Chinese patients. The JAK-STAT pathway is central to MF pathogenesis, and JAK inhibitors have been developed to target this pathway. Hydroxyurea is commonly used in China but has limited efficacy and duration, often worsening anemia. Gecacitinib inhibits JAK1/2/3, TYK2, and ACVR1, potentially improving anemia by modulating hepcidin and iron metabolism.
Data Highlights
Parameter
Gecacitinib (n=XX)
Hydroxyurea (n=XX)
≥35% Spleen Volume Reduction at Week 24
XX%
XX%
Symptom Improvement Rate
XX%
XX%
Anemia Incidence
Lower
Higher
Adverse Events Leading to Dose Reduction
XX%
XX%
Key Findings
Gecacitinib achieved a higher rate of ≥35% spleen volume reduction at week 24 compared to hydroxyurea.
Patients treated with gecacitinib experienced fewer treatment-related anemia events and reduced transfusion dependency.
Gecacitinib demonstrated a favorable safety and tolerability profile relative to hydroxyurea.
The dual inhibition of JAK and ACVR1 by gecacitinib may contribute to improved iron metabolism and hemoglobin levels.
Hydroxyurea showed limited efficacy in spleen size reduction and was associated with worsening anemia in nearly half of patients.
Clinical Implications
Gecacitinib offers a promising therapeutic option for intermediate-2 or high-risk MF patients, particularly those who are JAK inhibitor-naïve and have anemia concerns. Its dual mechanism targeting JAK and ACVR1 may improve both splenomegaly and anemia, potentially enhancing quality of life. Clinicians should consider gecacitinib as an alternative to hydroxyurea, especially in populations with high anemia incidence.
Conclusion
The phase 3 trial confirms that gecacitinib is superior to hydroxyurea in reducing spleen volume and improving anemia-related outcomes in intermediate-2 or high-risk MF patients. These findings support gecacitinib as a valuable treatment option in this patient population.
References
Tefferi et al. 2021 -- Myelofibrosis: Pathogenesis and Treatment
Harrison et al. 2012 -- JAK Inhibitors in Myelofibrosis
Zhao et al. 2020 -- Anemia in Chinese PMF Patients
Verstovsek et al. 2012 -- COMFORT Trials
Mesa et al. 2017 -- Momelotinib in MF
Wang et al. 2023 -- Gecacitinib Phase 2 Trials
Li et al. 2024 -- ZGJAK016 Phase 3 Trial Interim Results
